Oral Mouth Care and Mucositis

  • Denise MillsEmail author
  • Anne Marie Maloney
Part of the Pediatric Oncology book series (PEDIATRICO)


Oral mucositis is one of the most common and distressing side effects of cancer therapy and results from damage to the mucosal lining of the gastrointestinal tract due to radiation therapy and chemotherapy. Mucositis is characterized by oral erythema, ulceration, and pain and is seen as a continuum from limited patches of mildly sore erythematous mucosae to diffuse areas of painful ulceration and pseudomembranes. The oncology health care team must proactively assess and manage the oral health of pediatric oncology patients before, during and after cancer therapy. This chapter describes the incidence, etiologies, and treatments of oral mucositis and summarizes general oral health care for pediatric oncology patients. Current evidence-based guidelines are reviewed in order to aid pediatric oncology practitioners on best practice for the oral health of their patients.


Oral Health Hematopoietic Stem Cell Transplantation Oral Mucositis Allogeneic Hematopoietic Stem Cell Transplantation Oral Care 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abramoff MM, Lopes NN, Lopes LA et al (2008) Low-level laser therapy in the prevention and treatment of chemotherapy-induced oral mucositis in young patients. Photomed Laser Surg 26:393–400CrossRefPubMedGoogle Scholar
  2. Allen G, Logan R, Gue S (2010) Oral manifestations of cancer treatment in children: a review of the literature. Clin J Oncol Nurs 14:481–490CrossRefPubMedGoogle Scholar
  3. American Academy of Pediatric Dentistry (2013) Guideline on dental management of pediatric patients receiving chemotherapy, hematopoietic stem cell transplantation, and/or radiation. Pediatr Dent 35:E185–E193Google Scholar
  4. Anderson PM, Schroeder G, Skubitz KM (1998) Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 83:1433–1439CrossRefPubMedGoogle Scholar
  5. Aquino VM, Harvey AR, Garvin JH et al (2005) A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant 36:611–616CrossRefPubMedGoogle Scholar
  6. Barasch A, Epstein J, Tilashalski K (2009) Palifermin for management of treatment-induced oral mucositis in cancer patients. Biol Targets Ther 3:111–116CrossRefGoogle Scholar
  7. Bensadoun RJ, Nair RG (2012) Low-level laser therapy in the prevention and treatment of cancer therapy-induced mucositis: 2012 state of the art based on literature review and meta-analysis. Curr Opin Oncol 24:363–370CrossRefPubMedGoogle Scholar
  8. Bjordal JM (2012) Low level laser therapy (LLLT) and World Association for Laser Therapy (WALT) dosage recommendations. Photomed Laser Surg 30:61–62CrossRefPubMedGoogle Scholar
  9. Chen CF, Wang RH, Cheng SN, Chang YC (2004) Assessment of chemotherapy-induced oral complications in children with cancer. J Pediatr Oncol Nurs 21:33–39CrossRefPubMedGoogle Scholar
  10. Cheng KK, Lee V, Li CH et al (2012) Oral mucositis in pediatric and adolescent patients undergoing chemotherapy: the impact of symptoms on quality of life. Support Care Cancer 20:2335–2342CrossRefPubMedGoogle Scholar
  11. Clarkson JE, Eden OB (1998) Dental health in children with cancer. Arch Dis Child 78:560–561CrossRefPubMedCentralPubMedGoogle Scholar
  12. Clarkson JE, Worthington HV, Eden OB (2007) Interventions for preventing oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev 1:CD003807Google Scholar
  13. Clarkson JE, Worthington HV, Furness S et al (2010) Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev (4):CD001973Google Scholar
  14. Cruz LB, Ribeiro AS, Rech A et al (2007) Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy. Pediatr Blood Cancer 48:435–440CrossRefPubMedGoogle Scholar
  15. Eilers J, Million R (2011) Clinical update: prevention and management of oral mucositis in patients with cancer. Semin Oncol Nurs 27:e1–e16CrossRefPubMedGoogle Scholar
  16. Eilers J, Berger AM, Petersen MC (1988) Development, testing, and application of the oral assessment guide. Oncol Nurs Forum 15:325–330PubMedGoogle Scholar
  17. Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T (2009) Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev 1:CD006706Google Scholar
  18. Glenny AM, Gibson F, Auld E (2010) The development of evidence-based guidelines on mouth care for children, teenagers and young adults treated for cancer. Eur J Cancer 46:1399–1412CrossRefPubMedGoogle Scholar
  19. Guyatt G, Gutterman D, Baumann MH et al (2006) Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 129:174–181CrossRefPubMedGoogle Scholar
  20. Jacobs S, Baggott C, Agarwal R et al (2013) Validation of the Children’s International Mucositis Evaluation Scale (ChIMES) in paediatric cancer and SCT. Br J Cancer 109:2515–2522Google Scholar
  21. Keefe DM, Gibson RJ (2007) Mucosal injury from targeted anti-cancer therapy. Support Care Cancer 15:483–490CrossRefPubMedGoogle Scholar
  22. Kuhn A, Porto FA, Miraglia P, Brunetto AL (2009) Low-level infrared laser therapy in chemotherapy-induced oral mucositis: a randomized placebo-controlled trial in children. J Pediatr Hematol Oncol 31:33–37CrossRefPubMedGoogle Scholar
  23. Lalla RV, Sonis ST, Peterson DE (2008) Management of oral mucositis in patients who have cancer. Dent Clin North Am 52:61–77, viiiCrossRefPubMedCentralPubMedGoogle Scholar
  24. Lalla RV, Latortue MC, Hong CH et al (2010) A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer 18:985–992Google Scholar
  25. Langner S, Staber PB, Schub N et al (2008) Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant 42:275–279CrossRefPubMedGoogle Scholar
  26. Lauritano D, Petruzzi M, Di Stasio D, Lucchese A (2014) Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case-control study. Int J Oral Sci 6:27–30CrossRefPubMedCentralPubMedGoogle Scholar
  27. McDonnell AM, Lenz KL (2007) Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis. Ann Pharmacother 41:86–94CrossRefPubMedGoogle Scholar
  28. Posner MR, Haddad RI (2007) Novel agents for the treatment of mucositis. J Support Oncol 5:33–39PubMedGoogle Scholar
  29. Rubenstein EB, Peterson DE, Schubert M et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026–2046CrossRefPubMedGoogle Scholar
  30. Scully C, Epstein J, Sonis S (2003) Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. Head Neck 25:1057–1070CrossRefPubMedGoogle Scholar
  31. Scully C, Sonis S, Diz PD (2006) Oral mucositis. Oral Dis 12:229–241CrossRefPubMedGoogle Scholar
  32. Sonis ST (2004) A biological approach to mucositis. J Support Oncol 2:21–32Google Scholar
  33. Sonis ST (2009) Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 45:1015–1020CrossRefPubMedGoogle Scholar
  34. Sonis ST (2011) Oral mucositis. Anticancer Drugs 22:607–612CrossRefPubMedGoogle Scholar
  35. Sonis ST, Eilers JP, Epstein JB (1999) Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer 85:2103–2113CrossRefPubMedGoogle Scholar
  36. Sonis ST, Elting LS, Keefe D (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995–2025CrossRefPubMedGoogle Scholar
  37. Sonis ST (2007) Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 5:3–11Google Scholar
  38. Spielberger R, Stiff P, Bensinger W et al (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590–2598CrossRefPubMedGoogle Scholar
  39. Srinivasan A, Kasow KA, Cross S et al (2012) Phase I study of the tolerability and pharmacokinetics of palifermin in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18:1309–1314CrossRefPubMedCentralPubMedGoogle Scholar
  40. Storey B (2007) The role of oral glutamine in pediatric bone marrow transplant. J Pediatr Oncol Nurs 24:41–45CrossRefPubMedGoogle Scholar
  41. Sung L, Tomlinson GA, Greenberg ML et al (2007) Validation of the oral mucositis assessment scale in pediatric cancer. Pediatr Blood Cancer 49:149–153CrossRefPubMedGoogle Scholar
  42. Tomlinson D, Judd P, Hendershot E et al (2007) Measurement of oral mucositis in children: a review of the literature. Support Care Cancer 15:1251–1258Google Scholar
  43. Tomlinson D, Gibson F, Treister N et al (2008a) Challenges of mucositis assessment in children: expert opinion. Eur J Oncol Nurs 12:469–475CrossRefPubMedGoogle Scholar
  44. Tomlinson D, Isitt JJ, Barron RL et al (2008b) Determining the understandability and acceptability of an oral mucositis daily questionnaire. J Pediatr Oncol Nurs 25:107–111CrossRefPubMedGoogle Scholar
  45. Tomlinson D, Judd P, Hendershot E et al (2008c) Establishing literature-based items for an oral mucositis assessment tool in children. J Pediatr Oncol Nurs 25:139–147CrossRefPubMedGoogle Scholar
  46. Tomlinson D, Gibson F, Treister N et al (2009) Understandability, content validity, and overall acceptability of the Children’s International Mucositis Evaluation Scale (ChIMES): child and parent reporting. J Pediatr Hematol Oncol 31:416–423CrossRefPubMedGoogle Scholar
  47. Tomlinson D, Gibson F, Treister N et al (2010) Refinement of the Children’s International Mucositis Evaluation Scale (CHiMES): child and parent perspectives on understandability, content validity and acceptability. Eur J Oncol Nurs 14:29–41Google Scholar
  48. Tomlinson D, Ethier MC, Judd P et al (2011) Reliability and construct validity of the oral mucositis daily questionnaire in children with cancer. Eur J Cancer 47:383–388Google Scholar
  49. Treister N, Sonis S (2007) Mucositis: biology and management. Curr Opin Otolaryngol Head Neck Surg 15:123–129Google Scholar
  50. Vitale KM, Violago L, Cofnas P et al (2014) Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases. Pediatr Transplant 18:211–216CrossRefPubMedGoogle Scholar
  51. Ware E, Smith M, Henderson M et al (2009) The effect of high-dose enteral glutamine on the incidence and severity of mucositis in paediatric oncology patients. Eur J Clin Nutr 63:134–140CrossRefGoogle Scholar
  52. Worthington HV, Clarkson JE, Khalid T et al (2010) Interventions for treating oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev 7:CD001972Google Scholar
  53. Worthington HV, Clarkson JE, Bryan G et al (2011) Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 4:CD000978Google Scholar

Copyright information

© Springer Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Division of Hematology/OncologyThe Hospital for Sick ChildrenTorontoCanada

Personalised recommendations